Caitong Securities: First gives JD Health (06618.HK) a "buy" rating, optimistic about its long-term investment value.

According to the WiseFinance APP, Caitong Securities released a research report stating that they have initiated coverage on JD Health (06618.HK) with a "buy" rating. They predict that the company's revenue for 2025-2027 will be 70.9/82.4/94.2 billion yuan, and adjusted net profit attributable to shareholders will be 5.7/6.2/7.2 billion yuan, respectively. As a leading domestic pharmaceutical e-commerce company, JD Health has significant supply chain and fulfillment advantages. It is expected to continue benefiting from the increasing online penetration rate of pharmaceutical products and the opening up of online payment permissions for medical insurance. The company is seen as having long-term investment value.